Raltegravir

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

HIV

Conditions

HIV, Osteopenia, Osteoporosis, HIV Infections

Trial Timeline

Oct 1, 2009 → Apr 1, 2014

NCT ID

NCT00939874

About Raltegravir

Raltegravir is a approved stage product being developed by Merck for HIV. The current trial status is completed. This product is registered under clinical trial identifier NCT00939874. Target conditions include HIV, Osteopenia, Osteoporosis.

What happened to similar drugs?

20 of 20 similar drugs in HIV were approved

Approved (20) Terminated (1) Active (0)

✅Generic HAART Triomune : d4T, 3TC, NVP + Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABVCiplaApproved

✅Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableAbbVieApproved

✅Lopinavir/RitonavirAbbVieApproved

✅Ritonavir boosted Atazanavir + Raltegravir + TDF/FTC (or 3TC)MerckApproved

✅raltegravirMerckApproved

✅Kaletra + Isentress + Pre-study antiretroviral regimenMerckApproved

✅DOR/3TC/TDFMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00377065	Pre-clinical	Completed	—	—	HIV Infections
NCT03732625	Approved	UNKNOWN	May 1, 2019	Jan 1, 2021	HIV Infections
NCT03667547	Approved	Completed	Sep 27, 2018	Oct 23, 2018	Human Immunodeficiency Virus (HIV) Infection
NCT03374358	Approved	Completed	Jan 10, 2018	Nov 30, 2019	HIV Seropositivity
NCT02097108	Phase 2	Completed	May 1, 2014	Dec 1, 2015	HIV Infections
NCT01978743	Pre-clinical	Completed	Jan 1, 2014	Jan 1, 2017	HIV
NCT01767701	Phase 2	Completed	Apr 1, 2013	Sep 1, 2014	Relapsing Remitting Multiple Sclerosis
NCT01453933	Approved	UNKNOWN	Jan 1, 2012	Dec 1, 2014	HIV Infection
NCT01620736	Phase 2	Withdrawn	Jan 1, 2012	Dec 1, 2014	Human T-cell Leukemia Virus Type 1 Infection
NCT01453192	Phase 3	Completed	Dec 1, 2011	Nov 1, 2015	HIV-1 Infection
NCT01448486	Approved	Terminated	Oct 1, 2011	Oct 1, 2013	Human Immunodeficiency Virus (HIV)
NCT01327482	Pre-clinical	Completed	Oct 1, 2011	—	HIV
NCT01325051	Phase 1	Completed	Apr 1, 2011	Nov 1, 2011	Healthy Volunteer
NCT01042652	Pre-clinical	UNKNOWN	Feb 1, 2011	Jun 1, 2012	HIV
NCT01164605	Pre-clinical	UNKNOWN	Oct 1, 2010	Jun 1, 2013	HIV Infection
NCT01087840	Approved	Completed	Jul 1, 2010	Jul 1, 2012	HIV Prevention
NCT01027182	Phase 1	Completed	Dec 1, 2009	Mar 1, 2010	Human Immunodeficiency Virus
NCT00939874	Approved	Completed	Oct 1, 2009	Apr 1, 2014	HIV
NCT00807443	Phase 2	Completed	Sep 1, 2009	Dec 1, 2011	HIV-1
NCT00887653	Phase 3	Completed	May 1, 2009	Apr 1, 2014	HIV

Competing Products

20 competing products in HIV

See all competitors

Product	Company	Stage	Hype Score
DOR/ISL	Merck	Phase 2	35
Dolutegravir 50 mg twice daily + Dolutegravir placebo twice daily	Shionogi	Phase 3	40
GSK1265744 10 mg oral solution + GSK1265744 5 mg tablet + GSK1265744 5 mg tablet	Shionogi	Phase 1	29
GW810781	Shionogi	Phase 2	35
Generic HAART Triomune : d4T, 3TC, NVP + Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV	Cipla	Approved	43
Antiretroviral Therapy (ART) + Baricitinib (LY3009104) 2 mg	Eli Lilly	Phase 2	42
Epoetin alfa	Johnson & Johnson	Pre-clinical	26
Levofloxacin	Johnson & Johnson	Phase 1	29
SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo	Jiangsu Hengrui Medicine	Phase 1	29
ABBV-181 + Placebo	AbbVie	Phase 1	29
ABBV-382 + ABBV-382 + Placebo for ABBV-382	AbbVie	Phase 1	29
Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available	AbbVie	Approved	43
lopinavir/ritonavir + lamivudine	AbbVie	Pre-clinical	26
Lopinavir/Ritonavir	AbbVie	Approved	43
Budigalimab + Placebo + Budigalimab + Placebo	AbbVie	Phase 1	29
Budigalimab + Placebo for Budigalimab + ABBV-382 + Placebo for ABBV-382 + Budigalimab	AbbVie	Phase 2	27
CVC 150 mg + CVC 300 mg	AbbVie	Phase 2	35
Rosuvastatin 10 mg. daily for 96 weeks + Placebo	AstraZeneca	Phase 2	35
Raltegravir + Placebo + Current ART	Merck	Phase 3	40
Indinavir sulfate + Lamivudine + Zidovudine	Merck	Phase 3	40